Surfaxin

Chemical Namelucinactant
Dosage FormSuspension (intratracheal; 8.5mL)
Drug ClassLung surfactants
SystemRespiratory
CompanyDiscovery Laboratories Inc.
Approval Year2012

Indication

  • Indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Last updated on 5/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Surfaxin (lucinactant) Prescribing Information2012Discovery Laboratories, Inc., Warrington, PA